CACNA1B and depressive disorder: In 2024, TBG and IBG were reported to suppress several nicotinic acetylcholine receptors (nAchRs), γ‐aminobutyric acid type A receptors (GABAARs), and N‐type voltage‐gated calcium channels (Cav2.2) in both humans and rats, suggesting that they are involved in other mental disorders, such as anxiety, depression, and addiction, as well; likewise, the contribution of iboga congeners as antineuropathic drugs is expected.[151]